A Phase 4 interventional study of Oxycodone and Placebo in Labor Pain, sponsored by Kuopio University Hospital. Status unknown at 1 site in Finland. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-16.
Sponsored by Kuopio University Hospital · Phase 4, Interventional, and Treatment
Oxycodone is used to treat pain in early labor, however the effect of oxycodone to placental or fetal circulation has not been evaluated. Oxycodone is increasingly used to treat labor pain in the early phase. The aim of the randomised, double blinded, placebo controlled study was to evaluate the effects of oxycodone in placental circulation, efficacy and safety of oxycodone and the effects to the newborn.
396 studies on the registry are indexed under Labor Pain; 66 are open to participants now.
This study's enrollment of 22 is below the median of 100 across 326 interventional studies indexed under Labor Pain.
Browse Labor Pain studies →Kuopio University Hospital is the lead sponsor of 132 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
oxycodone planned for pain relief
Exclusion Criteria:
No oxycodone planned
The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
Drug: Placebo
The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
Drug: Oxycodone
The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
placental blood flow
Placental blood flow is measured with doppler ultrasound
Time frame: from zero hours to two hours after the first study drug
uterine arterial flow
uterine arterial flow is measured with doppler ultrasound
Time frame: from zero hours to two hours after the first study drug
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kuopio University Hospital